Oncotelic Therapeutics, Inc. (OTLC) stock
Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $8.66M
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- 0.03
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- $249.30M
- EPS, diluted
- $0.59
- Book value per share
- $0.57
- Diluted shares
- 468M
Trading
- Previous close
- $0.02
- Open
- $0.02
- Day's range
- $0.02 – $0.02
- Volume
- 204,601
- Average volume (20 days)
- 480,199
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | OTLC | S&P 500 | Difference | OTLC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.9% | +0.6% | −21.6 pts | ||
| 3 months | -54.9% | +3.4% | −58.3 pts | ||
| Year to date | -76.4% | +13.3% | −89.7 pts | ||
| 1 year | -81.4% | +16.6% | −98.0 pts | ||
| 3 years | -53.8% | +86.4% | −140.1 pts | -22.7% | +23.1% |
| 5 years | -85.8% | +81.9% | −167.6 pts | -32.3% | +12.7% |
| 10 years | -96.5% | +318.9% | −415.4 pts | -28.5% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Oncotelic Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Oncotelic Therapeutics
Pharmaceutical Preparations
Oncotelic Therapeutics, Inc. is a biopharmaceutical enterprise focused on researching, developing, and commercializing therapeutic treatments. The company concentrates its operational endeavors on pharmaceutical solutions designed to address oncologic indications and critical viral conditions. Its development initiatives feature innovative proprietary candidates, including targeted antisense oligodeoxynucleotide therapies addressing transforming growth factor-beta and specialized synthetic formulations intended for diverse clinical applications across medicine.
Company profile, executives and historyOncotelic Therapeutics stock: common questions
What is Oncotelic Therapeutics's stock price?
OTLC closed at $0.02 on Oct 19, 2026, up 11.45% on the day.
What is Oncotelic Therapeutics's market cap?
Oncotelic Therapeutics was worth $8.66M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is OTLC's P/E ratio?
OTLC trades at 0.0 times earnings, based on diluted earnings per share of $0.59 over fiscal 2025.
Does Oncotelic Therapeutics pay a dividend?
No. Oncotelic Therapeutics has not paid a cash dividend over the last twelve months.
How has OTLC stock performed over the past year?
Including dividends, OTLC returned -81.4% over the past year, against +16.6% for the S&P 500.
Who are Oncotelic Therapeutics's competitors?
Companies most similar to Oncotelic Therapeutics by business, industry and size include APLM, MAIA, GERN, OCS, RARE.
See a number that looks wrong?